113 related articles for article (PubMed ID: 696099)
21. [Various features of dopamine metabolism in schizophrenia].
Anokhina IP; Kogan BM
Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(9):1343-7. PubMed ID: 6798791
[TBL] [Abstract][Full Text] [Related]
22. Excretion of catecholamines in relatives of patients with familial neuroblastoma.
Piöchl E; Käser H; Klein H
Cancer Res; 1976 Jan; 36(1):10-12. PubMed ID: 1247989
[TBL] [Abstract][Full Text] [Related]
23. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
24. L-dopa reversal of muscular spasm, vomiting and insomnia in a patient with an atypical form of familial dystonia.
Coleman MP; Barnet A
Trans Am Neurol Assoc; 1969; 94():91-5. PubMed ID: 4313967
[No Abstract] [Full Text] [Related]
25. [Excretion of dopamine, noradrenaline, adrenaline, vanilmandelic acid and 5-hydroxyindoleacetic acid in the urine of volunteers treated with adepren].
Tiutiulkova NI; Gorancheva IuI
Eksp Med Morfol; 1975; 14(4):187-9. PubMed ID: 1222713
[TBL] [Abstract][Full Text] [Related]
26. [Reactivity of the DOPA--dopamine--noradrenaline--adrenaline system in epileptics].
Karlov VA; Gleĭzer MA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(6):810-5. PubMed ID: 6410626
[TBL] [Abstract][Full Text] [Related]
27. Elevation of urinary catecholamines and their metabolites following tyrosine administration in humans.
Alonso R; Gibson CJ; Wurtman RJ; Agharanya JC; Prieto L
Biol Psychiatry; 1982 Jul; 17(7):781-90. PubMed ID: 7115832
[TBL] [Abstract][Full Text] [Related]
28. Hereditary Parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication.
Allen N; Knopp W
Adv Neurol; 1976; 14():201-13. PubMed ID: 942621
[No Abstract] [Full Text] [Related]
29. [Dopa-sensitive dystonia].
Rondot P; Aicardi J; Goutières F; Ziegler M
Rev Neurol (Paris); 1992; 148(11):680-6. PubMed ID: 1303557
[TBL] [Abstract][Full Text] [Related]
30. [Administration of the catecholamine precursor, L-DOPA, for evaluating their in vivo biosynthesis in hypertension].
Kiseleva ZM; Parfenova EV; Erina EV; Shkhvatsabaia IK
Kardiologiia; 1979 Oct; 19(10):55-60. PubMed ID: 502171
[TBL] [Abstract][Full Text] [Related]
31. Changes in urinary excretion of catecholamines and their metabolites in pediatric dental patients.
Sakuma N; Nagasaka N
ASDC J Dent Child; 1996; 63(2):118-22. PubMed ID: 8708120
[TBL] [Abstract][Full Text] [Related]
32. [Catecholamine excretion in children with neurogenic tumors of the mediastinum].
Stepanov EA; Bukhny AE; Bol'shakova TD; Lukicheva TI
Khirurgiia (Mosk); 1972 Jun; 48(6):125-8. PubMed ID: 5043043
[No Abstract] [Full Text] [Related]
33. [Sensitivity and specificity of the determination of urinary catecholamines and their acid metabolites in the diagnosis of neuroblastoma in children].
Horsmans Y; Desager JP; Harvengt C
Bull Cancer; 1990; 77(10):985-9. PubMed ID: 2249018
[TBL] [Abstract][Full Text] [Related]
34. [Pathogenetic treatment of various hereditary extrapyramidal disorders with new drugs].
Markowa ED; Hausmanowa-Petrusewicz I; Alijewa LM; Friedman A; Insarowa NG
Neurol Neurochir Pol; 1981; 15(4):403-6. PubMed ID: 7329507
[TBL] [Abstract][Full Text] [Related]
35. The pattern of urinary catecholamines and their metabolites in Duchenne myopathy, in relation to disease evolution.
Dalmaz Y; Peyrin L; Mamelle JC; Tuil D; Gilly R; Cier JF
J Neural Transm; 1979; 46(1):17-34. PubMed ID: 501348
[TBL] [Abstract][Full Text] [Related]
36. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
Davidson DF; Grosset K; Grosset D
Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
[TBL] [Abstract][Full Text] [Related]
37. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
Mars H
Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
[No Abstract] [Full Text] [Related]
38. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
[No Abstract] [Full Text] [Related]
39. [Evaluation of the usefulness for measuring catecholamines and their principle metabolites in the diagnosis of pheochromocytoma].
Wocial B; Januszewicz W; Gryglas P; Januszewicz A; Feltynowski T; Lapiński M
Przegl Lek; 1997; 54(11):793-8. PubMed ID: 9501691
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostic and therapeutic problems in dystonia musculorum deformans].
Fraioli B; Contratti F; Baldassarre L
Riv Neurol; 1976; 46(1):73-80. PubMed ID: 796956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
